TNF and myelodysplastic syndrome: Despite aggressive management, BD-MDS patients exhibit poor responses to conventional therapies, including corticosteroids and tumor necrosis factor-alpha (TNF-α) inhibitors, with mortality rates exceeding 25% (6, 9).